- INFI (click for stock research page) presented 10/21 at the BioCentury Newsmakers Conference (find webcast link and complete biotech webcast calendar on Upcoming Events page)
- We retain US commerical rights to all of our oncology and inflammation programs
- As of IPI-926 presentation at ASCO (click here for details), PFS not yet hit, was at 5.5m. Compare this to historical data which is <3m for gemcitabine alone
- IPI-926 myelofibrosis trial initated 10/2011 other agents in development for this indication just reduce spleen size and address symtpoms...do no address the underlying disease
- chondrosarcoma - surgery for this condition is incredibly deforming/disfiguring because it is localized in major joints. We are now actively enrolling, seeking about 140 pts 2:1 randomization with crossover at about 50 sites.
- IPI-504 re HSP90 ocular toxicity - we did see toxicity. [all other times they have said "we have not seen significant ocular toxicity"...now dropped the word significant]
- heavy smokers make up ~2/3 of NSCLC, KRAS mutants make up 30%, squamous cell histology makes up 35%- we have covered these populations in phase 2 trials
- IPI-926 pancreatic cancer trial enrollment is complete